What are the challenges associated with identifying risk genes for Alzheimer’s disease? What more needs to be done to successfully translate this genetic data into potential therapeutics? Watch our video with Owen Peters to find out more.
What might the mechanisms behind circadian dysfunction in the early stages of dementia be? What more needs to be done to successfully translate this into the clinic? Watch our video with Marco Brancaccio to find out.
At the UK–Korea Neuroscience Symposium (12–13 August, London, UK), we had the fantastic opportunity of interviewing Justin Lee (Institute for…
In this video, we spoke with Kei Cho (UK DRI, King’s College London, UK) to find out more about the UK–Korea Neuroscience Symposium and how this collaboration has developed over the last few years.
What are the main challenges surrounding primary prevention trials for Alzheimer’s? Should researchers be exploring alternative avenues to amyloid-β in these trials? Take a look at our interview with Randall Bateman to find out more.
At the Glial meeting in Portugal, we had the fantastic opportunity of interviewing Pascale Eede and Verena Haage about their research with astrocytes and microglia, as well as their experiences on acquiring viable glial cells from adult brain tissues.
Webinar now available on demand. A comprehensive look at the evolving requirements for early phase CNS drug and cannabinoid development, with recommendations for regulatory strategy and marketing success.
In this interview from the Video Journal of Biomedicine, Hannah Brown (Ipsos Healthcare, London, UK) discusses physician and patient treatment decision-making for relapsing–remitting multiple sclerosis.
What are the challenges surrounding clinical trial design for genetic therapies in terms of neurodegenerative diseases? What technological advances could help bring these therapies to the clinic more quickly? Find out in our video interview with Sarah Tabrizi.
Genetic therapies represent a remarkable avenue for potentially slowing and preventing neurodegenerative diseases. This includes a first-in-human, gene-silencing treatment for Alzheimer’s disease. Find out more on this from Catherine Mummery.